PERRONE, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 1.972
AS - Asia 1.484
EU - Europa 1.243
AF - Africa 123
SA - Sud America 75
OC - Oceania 1
Totale 4.898
Nazione #
US - Stati Uniti d'America 1.958
VN - Vietnam 489
CN - Cina 394
SG - Singapore 339
GB - Regno Unito 302
SE - Svezia 197
DE - Germania 156
IT - Italia 151
FR - Francia 86
HK - Hong Kong 75
IN - India 66
RU - Federazione Russa 65
UA - Ucraina 62
NL - Olanda 56
BR - Brasile 47
IE - Irlanda 45
TG - Togo 35
CH - Svizzera 31
ZA - Sudafrica 30
CI - Costa d'Avorio 26
FI - Finlandia 25
JP - Giappone 21
EE - Estonia 18
PH - Filippine 16
BG - Bulgaria 14
KR - Corea 14
BE - Belgio 13
AR - Argentina 12
SC - Seychelles 12
CA - Canada 11
TH - Thailandia 11
JO - Giordania 10
TR - Turchia 10
NG - Nigeria 9
IR - Iran 8
BD - Bangladesh 6
CO - Colombia 5
LB - Libano 5
PL - Polonia 5
TW - Taiwan 5
AT - Austria 4
EC - Ecuador 4
CL - Cile 3
DZ - Algeria 3
ES - Italia 3
IL - Israele 3
IQ - Iraq 3
LT - Lituania 3
MA - Marocco 3
RO - Romania 3
VE - Venezuela 3
EG - Egitto 2
GR - Grecia 2
KE - Kenya 2
NP - Nepal 2
PK - Pakistan 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
AZ - Azerbaigian 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
HR - Croazia 1
ID - Indonesia 1
MX - Messico 1
PA - Panama 1
PY - Paraguay 1
ZW - Zimbabwe 1
Totale 4.898
Città #
Southend 268
Ashburn 250
Singapore 230
Chandler 218
Fairfield 183
Dong Ket 130
Woodbridge 106
Ann Arbor 83
Seattle 82
Houston 77
Wilmington 77
Beijing 73
Cambridge 72
Hong Kong 71
Ho Chi Minh City 67
Hanoi 63
San Jose 63
Princeton 59
Dublin 45
Santa Clara 45
Bologna 40
Jacksonville 39
Boardman 38
Lomé 35
Nanjing 35
New York 34
Hefei 31
Abidjan 26
Bern 26
Bremen 25
Westminster 25
Helsinki 24
Padova 24
Los Angeles 23
Lauterbourg 20
Shenyang 19
Tokyo 19
Jinan 18
Buffalo 15
Changsha 15
Berlin 14
Frankfurt am Main 14
Sofia 14
Turin 14
Brussels 13
Hebei 13
Haiphong 12
Saint Petersburg 12
Redwood City 11
Amman 10
Seoul 10
Abeokuta 9
Da Nang 9
Mülheim 9
Nanchang 9
Falkenstein 7
Medford 7
San Diego 7
Tianjin 7
Verona 7
Guangzhou 6
Hangzhou 6
Jiaxing 6
Monmouth Junction 6
Montreal 6
Norwalk 6
Orem 6
Paris 6
Washington 6
Zhengzhou 6
Brooklyn 5
Hải Dương 5
Mahé 5
Milan 5
Munich 5
São Paulo 5
The Dalles 5
Wuhan 5
Amsterdam 4
Ardabil 4
Bangkok 4
Can Tho 4
Chicago 4
Crevalcore 4
Dallas 4
Dearborn 4
Denver 4
Falls Church 4
Johannesburg 4
Lanzhou 4
London 4
Pune 4
Redmond 4
Redondo Beach 4
Roubaix 4
Shanghai 4
Andover 3
Bengaluru 3
Bexley 3
Boston 3
Totale 3.185
Nome #
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 341
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 308
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 250
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 232
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 221
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 201
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 194
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 193
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 192
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 192
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 192
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 189
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 181
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 177
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 174
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 172
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 172
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 172
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 171
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 165
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 165
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 155
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 153
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 152
Proteasome inhibitors: Bortezomib in multiple myeloma 91
Totale 4.959
Categoria #
all - tutte 12.405
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.405


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021277 0 0 0 0 0 0 0 0 0 25 46 206
2021/2022606 96 15 32 41 51 34 7 30 20 65 107 108
2022/2023816 88 142 34 130 42 69 24 34 112 25 54 62
2023/2024207 10 32 14 20 25 65 11 5 2 8 6 9
2024/2025530 10 57 41 39 76 34 45 31 3 76 7 111
2025/20261.201 132 91 101 87 168 80 109 30 307 96 0 0
Totale 4.959